Valutazione clinico-ecografica dell'utilizzo di una nuova formulazione in mousse termosensibile di clobetasol propionato 0.05% in monoapplicazione giornaliera nel trattamento della psoriasi e in controlli sani

The aim of this open-label pilot study was to evaluate clinically, and through ultrasound imaging the response to treatment as well as the atrophogenic potential of once daily application of clobetasol propionate (CP) 0.05% foam on both psoriatic and healthy skin. Ten participants affected by mild to moderate plaque-type psoriasis were instructed to apply CP 0.05% foam once daily for up to 4 weeks. In addition, 10 healthy adult volunteers were enrolled and instructed to apply the foam to a 4x4 cm area on the volar aspect of the forearm once daily for 4 weeks. At the end of the study clinical and ultrasound resolution was observed in all psoriatic patients. No side effects were recorded. In healthy volunteers there was no evidence of atrophy and/or telangiectasia, and mean skin thickness before and after treatment was unchanged (1 mm). Our study has demonstrated that a prolonged use up to 30 days of once daily CP 0.05% foam application is a relatively safe therapeutic option in those cases in which treatment with very high-potency class I topical corticosteroid is advisable. Further blinded and vehicle-controlled investigations in a larger subject population are warranted.